141W94
From Health Encyclopedia
[edit]
See
[edit]
Facts (generated by robot; please edit if you find it inaccurate)
- 141W94 is a second generation protease inhibitor being developed by Glaxo Wellcome plc, Kissei Pharmaceutical Co.
- 141W94 is a novel HIV-1 protease inhibitor now in clinical trials.
- As 141W94 is synergistic with a variety of anti-HIV-1 agents and exhibits a unique cross resistance profile compared to other protease inhibitors, 141W94 is considered a good for combination therapy.
- 141W94 (VX-478) 141W94 is an investigational protease inhibitor under development by Glaxo Wellcome.
- 8152 HIV Infection in Children To see if 141W94 is safe and effective when combined with other antiretroviral drugs in fighting HIV infection in children.
Would you like to discuss or post question about 141W94 ? Click here !